PMID: 15216909Jun 26, 2004Paper

Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms

Current Drug Targets
M Veronica GavrielidesMarcelo G Kazanietz

Abstract

A series of both genetic and epigenetic factors have been implicated in the genesis and progression of prostate cancer. Recent evidence revealed that protein kinase C (PKC) isozymes play a crucial role in the control of cell proliferation and apoptosis in prostate cancer models, as well as in the transition from an androgen-dependent to an androgen-independent status. Indeed, PKCalpha and PKCdelta promote apoptosis in androgen-dependent prostate cancer cells. Due to the relevance of PKC isozymes in the control of cell cycle, both in G1/S and G2/M, the elucidation of such complex intracellular networks using cellular and animal models has become of outmost importance. In this review, we present the current knowledge on the regulation of apoptosis and tumorigenicity by PKC isozymes and the functional roles of cell cycle regulators in prostate carcinogenesis. The development of animal models where overexpression of discrete PKCs or cell cycle regulators is targeted to the prostate will greatly contribute to the understanding of the molecular basis of the disease, and more importantly, it will have profound implications for the development of novel strategies for prostate cancer therapy.

Citations

Sep 8, 2012·The Journal of Biological Chemistry·Rachana GargMarcelo G Kazanietz
Feb 9, 2010·Antioxidants & Redox Signaling·Carlotta GiorgiPaolo Pinton
Sep 6, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Amanda J Redig, Leonidas C Platanias
Dec 18, 2013·Oncogene·R GargM G Kazanietz
Jul 8, 2008·Leukemia & Lymphoma·Amanda J Redig, Leonidas C Platanias
Dec 13, 2005·Growth Factors·José Luis OlivaMarcelo G Kazanietz
Feb 24, 2009·Trends in Biochemical Sciences·T J Nelson, D L Alkon
Aug 30, 2008·Molecular Carcinogenesis·Liqing XiaoMarcelo G Kazanietz
Jul 1, 2006·Biochimica Et Biophysica Acta·Senena Corbalán-García, Juan C Gómez-Fernández
Dec 13, 2005·Journal of Biochemistry and Molecular Biology·Anatilde M Gonzalez-GuerricoMarcelo G Kazanietz
Aug 10, 2011·Biochimica Et Biophysica Acta·Sivalokanathan SarveswaranJagadananda Ghosh
Jan 13, 2011·Cell Cycle·Fernando BenavidesMarcelo G Kazanietz
May 25, 2016·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Xuejuan GaoLangxia Liu
Mar 27, 2007·Nature Reviews. Cancer·Erin M Griner, Marcelo G Kazanietz
Dec 29, 2007·The Journal of Biological Chemistry·Jose L OlivaMarcelo G Kazanietz
Aug 2, 2005·The Journal of Biological Chemistry·Motonori NakagawaMarcelo G Kazanietz
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Simon DialloFred Saad
May 30, 2015·Molecular Cancer Research : MCR·Alvaro Gutierrez-UzquizaMarcelo G Kazanietz
Sep 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beverly A Teicher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis